# A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors

Source: https://onco.cc/trials/nct07229638/  
OnCo record `nct07229638` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of SHR-9839(sc) For Injection in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A IB/II Phase Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07229638 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 70 participants planned, started 2026-02-27 and due to reach its primary completion in 2027-04. Interventions recorded: SHR-9839(sc) For Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07229638
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase IB/II Clinical Study on the Safety, Tolerability, and Efficacy of SHR-9839(sc) in Combination Anti-tumor Therapy in Patients With Solid Tumors
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT07229638: https://clinicaltrials.gov/study/NCT07229638

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07229638.json